Adalimumab, a fully human monoclonal antibody, is a newer member of the tumor necrosis factor-α antagonist class of drugs. The Food and Drug Administration approved it in 2008 for the treatment of moderate to severe chronic plaque psoriasis, and it has proved highly effective when compared with other conventional therapies. Herein we describe the indications, administration, contraindications, and potential adverse effects (e.g., immunosuppression) of adalimumab as well as its safety record for both short- and long-term use. An important advantage of adalimumab is that it can be administered by patients themselves.
KhraishiM.Comparative overview of safety of the biologics in rheumatoid arthritis. J Rheumatol.2009; 82: 25–32.
2.
YamauchiP.S., MauN.Adalimumab treats psoriasis in patients previously treated with etanercept: a case series. J Am Acad Dermatol.2009; 61(1): 158–61.
3.
SauratJ.H., StinglG., DubertretL., PappK., LangleyR.G.Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol.2007; 158: 558–66.
4.
ChenD.Adalimumab efficacy and safety in patients with moderate to severe chronic plaque psoriasis: preliminary findings from a 12–week dose-ranging trial. J Am Acad Dermatol.2004; 50(3): P1.
5.
PatelT., GordonK.B.Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol Ther.2004; 17: 427–31.
6.
GladmanD.D., MeaseP.J., RitchlinC.T.Adalimumab for long-term treatment of psoriatic arthritis. Arthritis Rheum.2007; 56(2): 476–88.
7.
MeaseP.J., GladmanD.D., RitchlinC.T.Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Arthritis Rheum.2005; 52(10): 3279–89.
8.
SchiffM.H., BurmesterG.R., KentJ.D., PanganA.L.Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis.2006; 65: 889–94.
9.
ScheinfeldN.A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatol Treat.2004; 15: 280–94.
10.
MoustouA.E., MatekovitsA., DessiniotiC.Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol.2009; 61(3): 486–504.
11.
GordonK.B., LangleyR.G., LeonardiC.Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol.2006; 55(4): 598–607.
12.
Abbott Laboratories. Full prescribing information for humira.2008.
13.
BreedveldF.B., WeismanM.H., KavanaughA.F.The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum.2006; 54(1): 26–37.
14.
ChewA.L., BennettA., SmithC.H.Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. Br J Dermatol.2004; 151: 492–6.
15.
ZeichnerJ.A., LebwohlM.G.Potential complications associated with the use of biologic agents for psoriasis. Dermatol Clin.2007; 25: 207–13.
16.
GordonK.B., BonishB.K., PateT.The tumour necrosis factor-α inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol.2005; 153: 945–53.
17.
de GannesG.C., GhoreishiM., PopeJ.Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions. Arch Dermatol.2007; 143: 223–31.
18.
DohertyS.D., VoorheesA.V., LebwohlM.G.National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol.2008; 59(2): 209–17.
19.
MössnerR., SchönM.P., ReichK.Tumor necrosis factor antagonist sin the therapy of psoriasis. Clin Dermatol.2008; 26: 486–502.
20.
AntwerpD.J.V., MartinS.J., KafriT.Suppression of TNF-α-induced apoptosis by NF-KB. Science.1996; 274: 787–9.
AsklingJ., ForedC.M., BaecklundE., BrandtL., BacklinC.Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis.2005; 64: 1414–20.
25.
GeborekP., BladströmA., TuressonC., GulfeA.Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis.2005; 64: 699–703.
26.
SabaN.S., KosseifiS.G., CharafE.A., HammadA.N.Adalimumab-induced acute myelogenic leukemia. South Med J.2008; 101(12): 1261–2.
27.
WolfeF., MichaudK.Biologic treatment of rheumatoid arthritis and the risk of malignancy. Arthritis Rheum.2007; 56(9): 2886–95.
28.
FulchieroG.J., SalvaggioH., DrabickJ.J.Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol.2007; 56(5): S65–7.
29.
StroberB., BergerE., CatherJ.A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. J Am Acad Dermatol.2009; 61(1): S1–46.
LebwohlM.G., BagelG., GelfandG.M.From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol.2008; 58(1): 94–105.
32.
CepedaE.J., WilliamsF.M., IshimoriM.L.The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis.2008; 67(5): 710–12.
33.
SaracenoR., ChimentiS.How to manage infections in the era of biologics?Dermatol Ther.2008; 21: 180–6.
34.
Callejas-RubioJ., Lopez-PerezNOCLTreatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol.2006; 25(4): 596–7.
35.
SfikakisP.P., IliopoulosA., ElezoglouA.Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum.2005; 52(8): 2513–8.
36.
ZellaG.C., WeinblattM.E., WinterH.S.Drug-induced lupus associated with infliximab and adalimumab in an adolescent with Crohn's disease. J Pediatr Gastroenterol Nutr.2009; 49: 355–8.
37.
ClarkL., LebwohlM.G.The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol.2008; 58: 443–6.
38.
NestorovI.Clinical pharmacokinetics of TNF antagonists: how do they differ?Semin Arthritis Rheum.2004; 34(5): 12–8.
39.
MenterA., TyringS.K., GordonK.Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol.2008; 58(1): 106–16.
40.
PisetskyD.S.Tumor necrosis factor blockers in rheumatoid arthritis. N Engl J Med.2000; 342: 810–1.
41.
TzuJ., KerdelF.From conventional to cutting edge: the new era of biologics in treatment of psoriasis. Dermatol Ther.2008; 21: 131–41.
